EU Data Helps Sandoz’s U.S. Clinical Program For Filgrastim

 
• By Derrick Gingery

Because FDA agreed data comparing Sandoz’s filgrastim to EU-approved Neupogen could serve as bridge for comparisons to U.S.-approved Neupogen, firm only needed two additional studies for its biosimilar application.

Sandoz Inc. illustrated the power of bridging data with its filgrastim biosimilar application. The company submitted eight studies in its data package, but only a fraction compared its filgrastim to its U.S.-approved reference product, Amgen Inc.’s Neupogen.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America